Search by Drug Name or NDC
NDC 00025-2818-31 CALAN SR 180 mg/1 Details
CALAN SR 180 mg/1
CALAN SR is a ORAL TABLET, FILM COATED, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is VERAPAMIL HYDROCHLORIDE.
MedlinePlus Drug Summary
Verapamil is used to treat high blood pressure and to control angina (chest pain). The immediate-release tablets are also used alone or with other medications to prevent and treat irregular heartbeats. Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 00025-2818-31Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Verapamil
Product Information
| NDC | 00025-2818 |
|---|---|
| Product ID | 0025-2818_f01a76e9-903f-4326-8eff-af7b09464b54 |
| Associated GPIs | 34000030100415 |
| GCN Sequence Number | 013670 |
| GCN Sequence Number Description | verapamil HCl TABLET ER 180 MG ORAL |
| HIC3 | A9A |
| HIC3 Description | CALCIUM CHANNEL BLOCKING AGENTS |
| GCN | 32471 |
| HICL Sequence Number | 000180 |
| HICL Sequence Number Description | VERAPAMIL HCL |
| Brand/Generic | Brand |
| Proprietary Name | CALAN SR |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | verapamil hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 180 |
| Active Ingredient Units | mg/1 |
| Substance Name | VERAPAMIL HYDROCHLORIDE |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA019152 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00025-2818-31 (00025281831)
| NDC Package Code | 0025-2818-31 |
|---|---|
| Billing NDC | 00025281831 |
| Package | 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0025-2818-31) |
| Marketing Start Date | 2020-12-16 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |